The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT02565628 ·Status: COMPLETED ·Phase: PHASE1

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease

NCT06596005 ·Status: COMPLETED ·Phase: PHASE2

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

NCT00006077 ·Status: COMPLETED ·Phase: PHASE2

2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD

NCT00209508 ·Status: COMPLETED ·Phase: PHASE2

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168 ·Status: COMPLETED ·Phase: PHASE2

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

NCT00623324 ·Status: COMPLETED ·Phase: PHASE2

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

NCT01634360 ·Status: TERMINATED ·Phase: PHASE2

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

NCT00297778 ·Status: COMPLETED ·Phase: PHASE4

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906 ·Status: COMPLETED ·Phase: PHASE1

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

NCT03436953 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

NCT06175767 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

NCT01172379 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

NCT04810104 ·Status: WITHDRAWN ·Phase: PHASE2

Nilotinib in Parkinson's Disease

NCT03205488 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Parkinson's Disease With Eliprodil

NCT00001929 ·Status: COMPLETED ·Phase: PHASE2

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

NCT00076492 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

NCT06773962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Mirabegron in Parkinson Disease and Impaired Cognition

NCT02536976 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

NCT01227265 ·Status: COMPLETED ·Phase: PHASE3

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

NCT00642356 ·Status: TERMINATED ·Phase: PHASE4

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

NCT01130493 ·Status: COMPLETED ·Phase: PHASE3

JP-1730 to Treat Parkinson's Disease

NCT00040209 ·Status: COMPLETED ·Phase: PHASE2